Clinical Trials Logo

Clinical Trial Summary

Celiac disease is the most common genetically related food intolerance, worldwide. It is an immune mediated intolerance to gluten (from wheat, barley, or rye) in genetically susceptible individuals .The disease primarily affects the small intestine, where it progressively leads to flattening of the small intestinal mucosa .


Clinical Trial Description

Within this definition, patients can further be defined as having silent, potential, or latent celiac disease. The term silent celiac disease refers to patients fulfilling the definition above, but presenting no symptoms. Typically, such diagnoses are made by screening asymptomatic individuals, who are at increased risk for celiac disease. The term potential celiac disease describes patients who have specific serum autoantibodies and may or may not have symptoms consistent with celiac disease, but lack evidence of the autoimmune damage to the intestinal mucosa. A final category of celiac patients is represented by the so-called latent celiac disease: individuals with normal mucosal morphology (like the potential) but known to have had a gluten-dependent enteropathy at some point in their life .

Malabsorption results from injury to the small intestine with loss of absorptive surface area, reduction of digestive enzymes, and consequential impaired absorption of micronutrients such as fat-soluble vitamins, iron and potentially B12 and folic acid. In addition, the inflammation exacerbates symptoms of malabsorption by causing net secretion of fluid that can result in diarrhea. The failure of absorption of adequate calories leads to weight loss, and the malabsorption results in abdominal pain and bloating .

A positive family history is a risk factor for celiac disease. The frequency of celiac disease is higher among first- and second-degree relatives of persons with celiac disease, although prevalence estimates range from 5 to 20 percent . Frequency of celiac disease is also higher among persons with other autoimmune diseases, such as type 1 diabetes mellitus, inflammatory luminal gastrointestinal disorders, Down syndrome, Turner's syndrome, IgA deficiency, and IgA nephropathy .

Gastrointestinal and extra-intestinal manifestations of celiac disease include diarrhea, abdominal pain, abdominal distention, anorexia, vomiting, constipation, failure to thrive, chronic fatigue, anemia, osteoporosis, aphthous stomatitis, elevated liver enzymes, joint/muscle pain, epilepsy, and peripheral neuropathy .

Clinical practice guidelines recommend to starting with the serum anti-tissue transglutaminase IgA antibodies (anti-tTG IgA) test as a diagnostic testing for celiac disease. The tTG IgA test is the standard method of testing for celiac disease . Clinical practice in guidelines the United States and Europe recommend intestinal biopsy to confirm the diagnosis of celiac disease (e.g., based on presence of villous atrophy hyperplasia of crypts, and increase of intraepithelial lymphocytes) and to distinguish celiac disease from other disorders affecting the small intestine. Intestinal biopsy may also be performed if clinical suspicion for celiac disease is high but serologic tests are negative . It has been suggested that a combination of serologic tests could be used to establish celiac disease diagnosis as an alternative to biopsy, but it is unclear how frequently celiac disease is diagnosed in the absence of biopsy in clinical practice. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04019223
Study type Observational
Source Assiut University
Contact Naglaa Abu faddan, professor
Phone 00201111872237
Email Naglaa.ibrahim@med.au.edu.eg
Status Not yet recruiting
Phase
Start date October 1, 2019
Completion date March 1, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04440501 - Virtual Reality to Teach, Improve Outcomes, and Engage (VIRTUE): Virtual Reality to Improve Gluten-Free Diet Knowledge in Pediatric Celiac Disease N/A
Enrolling by invitation NCT06179121 - "Adding DNA-test for Screening of HLA-DQ2 and DQ8 to Improve Early Diagnosis of Celiac Disease"
Recruiting NCT06324539 - Validation of a New Innovative Method for Specific Marker Detection in Celiac Disease
Completed NCT06359613 - Efficacy Assessment of Gluten Free Cupcakes N/A
Active, not recruiting NCT05548166 - Development of CELIAC-Q KIDS: A Patient-Reported Outcome Measure for Pediatric Celiac Disease
Recruiting NCT04014660 - Prevention av Autoimmunitet Med Laktobaciller N/A
Completed NCT03966625 - Serological Identification of Celiac Disease in Kids
Not yet recruiting NCT03244254 - Intestinal Fatty Acid-binding Protein (I-FABP) Levels in Pediatric Celiac Patients N/A
Recruiting NCT05132725 - Carbohydrate Counting and DASH Intervention Among Children With Diabetes and Celiac Disease. N/A
Enrolling by invitation NCT05084937 - Celiac Disease in Childhood-Adulthood Transition N/A
Active, not recruiting NCT04593888 - Gluten Reduction and Risk of Celiac Disease N/A
Recruiting NCT06007898 - Supporting Children and Young People to Live Well With Coeliac Disease N/A
Recruiting NCT06364735 - Entities and Variables Related to Catch-up Growth
Completed NCT04272983 - Population Study of the Prevalence of Celiac Disease and Other Gluten-dependent Disorders in Children and Adolescents
Not yet recruiting NCT06149507 - Effect of Acetaminophen Versus Ibuprofen in Treating Recurrent Apthous Ulcers in Pediatric Celiac Disease Phase 4
Completed NCT04240340 - Experiences of Disclosure in Adolescents With Coeliac Disease
Completed NCT03176095 - Celiac Disease Prevention With Probiotics N/A
Active, not recruiting NCT06038344 - Influence of a Gluten Free Food Guide on Diet Quality and Adherence to the GFD in Youth With Celiac Disease N/A
Completed NCT04533776 - Support for Adolescents With Celiac Disease N/A
Completed NCT03663309 - Assessment of Adherence to Gluten Free Diet in Children and Adolescents by Detection of Gluten in Faecal Samples.